Mark Allison

648 total citations
14 papers, 514 citations indexed

About

Mark Allison is a scholar working on Oncology, Physiology and Infectious Diseases. According to data from OpenAlex, Mark Allison has authored 14 papers receiving a total of 514 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 3 papers in Physiology and 2 papers in Infectious Diseases. Recurrent topics in Mark Allison's work include Renal Transplantation Outcomes and Treatments (2 papers), Drug Transport and Resistance Mechanisms (2 papers) and Antifungal resistance and susceptibility (2 papers). Mark Allison is often cited by papers focused on Renal Transplantation Outcomes and Treatments (2 papers), Drug Transport and Resistance Mechanisms (2 papers) and Antifungal resistance and susceptibility (2 papers). Mark Allison collaborates with scholars based in United States, Switzerland and Netherlands. Mark Allison's co-authors include María J. Gutiérrez, Alan Kivitz, Desmond Padhi, Christine Wang, Brian Stouch, Graham Jang, Amelia E. Pearsall, Ty McClure, Dawn Wilson and Matthew L. Sherman and has published in prestigious journals such as Blood, Antimicrobial Agents and Chemotherapy and Annals of the Rheumatic Diseases.

In The Last Decade

Mark Allison

13 papers receiving 501 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Allison United States 9 171 137 115 104 83 14 514
Haoyi Zheng United States 14 153 0.9× 32 0.2× 47 0.4× 17 0.2× 124 1.5× 33 509
Sameh R. Abul‐Ezz United States 14 133 0.8× 179 1.3× 63 0.5× 12 0.1× 41 0.5× 26 800
Amanda Freeman United States 11 177 1.0× 287 2.1× 95 0.8× 148 1.4× 10 0.1× 13 748
Marianne Keisu Sweden 13 52 0.3× 90 0.7× 35 0.3× 8 0.1× 92 1.1× 18 613
Richard Ho United States 15 98 0.6× 527 3.8× 108 0.9× 6 0.1× 88 1.1× 28 880
Jiraphun Jittikoon Thailand 14 133 0.8× 87 0.6× 151 1.3× 9 0.1× 11 0.1× 51 614
Bénédicte Bénéteau‐Burnat France 13 157 0.9× 32 0.2× 34 0.3× 7 0.1× 27 0.3× 28 550
Marshall Sack United States 11 88 0.5× 39 0.3× 27 0.2× 6 0.1× 27 0.3× 12 517
Dietmar Nagel Germany 12 81 0.5× 36 0.3× 7 0.1× 49 0.5× 44 0.5× 30 422
Daiki Tsuji Japan 14 137 0.8× 159 1.2× 46 0.4× 3 0.0× 20 0.2× 50 568

Countries citing papers authored by Mark Allison

Since Specialization
Citations

This map shows the geographic impact of Mark Allison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Allison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Allison more than expected).

Fields of papers citing papers by Mark Allison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Allison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Allison. The network helps show where Mark Allison may publish in the future.

Co-authorship network of co-authors of Mark Allison

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Allison. A scholar is included among the top collaborators of Mark Allison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Allison. Mark Allison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
3.
Shakeri‐Nejad, Kasra, Vassilios Aslanis, Louise Mooney, et al.. (2015). Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects. Clinical Therapeutics. 37(11). 2489–2505.e2. 13 indexed citations
4.
Attie, Kenneth M., Mark Allison, Ty McClure, et al.. (2014). A phase 1 study of ACE‐536, a regulator of erythroid differentiation, in healthy volunteers. American Journal of Hematology. 89(7). 766–770. 88 indexed citations
5.
Padhi, Desmond, Mark Allison, Alan Kivitz, et al.. (2013). Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study. The Journal of Clinical Pharmacology. 54(2). 168–178. 139 indexed citations
6.
7.
8.
Allison, Mark, et al.. (2012). OP0044 The effects of multiple doses of sclerostin antibody AMG 785 in healthy men and postmenopausal women with low bone mass. Annals of the Rheumatic Diseases. 71. 67–68. 2 indexed citations
9.
Brown, Karen, Joseph R. Walker, Robert J. Noveck, et al.. (2009). Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and Glyburide. The Journal of Clinical Pharmacology. 50(5). 554–565. 22 indexed citations
10.
Lefèvre, Gilbert, F. Pommier, G Sędek, et al.. (2008). Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly Subjects. The Journal of Clinical Pharmacology. 48(2). 246–252. 35 indexed citations
11.
Rohatagi, Shashank, James Lee, Magdy Shenouda, et al.. (2008). Pharmacokinetics of Amlodipine and Olmesartan After Administration of Amlodipine Besylate and Olmesartan Medoxomil in Separate Dosage Forms and as a Fixed‐Dose Combination. The Journal of Clinical Pharmacology. 48(11). 1309–1322. 28 indexed citations
12.
Liu, Ping, Kuan Gandelman, Robert R. LaBadie, et al.. (2007). Steady-State Pharmacokinetic and Safety Profiles of Voriconazole and Ritonavir in Healthy Male Subjects. Antimicrobial Agents and Chemotherapy. 51(10). 3617–3626. 61 indexed citations
13.
Hébert, Mary F., David K. Blough, Robert Townsend, et al.. (2005). Concomitant Tacrolimus and Micafungin Pharmacokinetics in Healthy Volunteers. The Journal of Clinical Pharmacology. 45(9). 1018–1024. 72 indexed citations
14.
Kovarik, John M., et al.. (2005). Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. British Journal of Clinical Pharmacology. 60(4). 434–437. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Haoyi Zheng Breakdown of academic impact, for papers by Sameh R. Abul‐Ezz Breakdown of academic impact, for papers by Amanda Freeman Breakdown of academic impact, for papers by Marianne Keisu Breakdown of academic impact, for papers by Richard Ho Breakdown of academic impact, for papers by Jiraphun Jittikoon Breakdown of academic impact, for papers by Bénédicte Bénéteau‐Burnat Breakdown of academic impact, for papers by Marshall Sack Breakdown of academic impact, for papers by Dietmar Nagel Breakdown of academic impact, for papers by Daiki Tsuji
Rankless by CCL
2026